Potential Benefits of Green Tea in Prostate Cancer Prevention and Treatment: A Comprehensive Review.
10.1007/s11655-024-4100-2
- Author:
Gui-Hong LIU
1
;
Ze-Qin YAO
1
;
Guo-Qiang CHEN
1
;
Ya-Lang LI
2
;
Bing LIANG
3
Author Information
1. Department of Urology, Sanya Central Hospital (The Third People's Hospital of Hainan Province), Sanya City, Hainan Province, 572000, China.
2. Department of Urology, Yuzhou People's Hospital, Xuchang City, Henan Province, 461670, China.
3. Department of Urology, Sanya Central Hospital (The Third People's Hospital of Hainan Province), Sanya City, Hainan Province, 572000, China. lala571437@sina.com.
- Publication Type:Review
- Keywords:
epigallocatechin gallate;
green tea;
prevention;
prostate cancer;
review;
treatment
- MeSH:
Humans;
Male;
Prostatic Neoplasms/drug therapy*;
Tea/chemistry*;
Catechin/pharmacology*
- From:
Chinese journal of integrative medicine
2024;30(11):1045-1055
- CountryChina
- Language:English
-
Abstract:
Prostate cancer is a prevalent and debilitating disease that necessitates effective prevention and treatment strategies. Green tea, a well-known beverage derived from the Camellia sinensis plant, contains bioactive compounds with potential health benefits, including catechins and polyphenols. This comprehensive review aims to explore the potential benefits of green tea in prostate cancer prevention and treatment by examining existing literature. Green tea possesses antioxidant, anti-inflammatory, and anti-carcinogenic properties attributed to its catechins, particularly epigallocatechin gallate. Epidemiological studies have reported an inverse association between green tea consumption and prostate cancer risk, with potential protection against aggressive forms of the disease. Laboratory studies demonstrate that green tea components inhibit tumor growth, induce apoptosis, and modulate signaling pathways critical to prostate cancer development and progression. Clinical trials and human studies further support the potential benefits of green tea. Green tea consumption has been found to be associated with a reduction in prostate-specific antigen levels, tumor markers, and played a potential role in slowing disease progression. However, challenges remain, including optimal dosage determination, formulation standardization, and conducting large-scale, long-term clinical trials. The review suggests future research should focus on combinatorial approaches with conventional therapies and personalized medicine strategies to identify patient subgroups most likely to benefit from green tea interventions.
